Spider-Man, Odyssey Help Power Box Office Comeback

Global box-office ticket sales are up 15% year over year, marking Hollywood's strongest year since 2019 as theater attendance rebounds. Five films have surpassed $1 billion in ticket sales, underscoring a broad recovery in cinema demand. The durability of the momentum remains a key question for theater operators and film studios.

Analysis

The cleanest monetization is not necessarily the studios: exhibitors and premium-format operators have the highest operating leverage to incremental attendance once fixed theater costs are covered. IMAX should capture a disproportionate share if event-film concentration persists, while Cinemark (CNK) is structurally better positioned than AMC (AMC) through lower leverage and less equity-dilution risk. Studios including Disney (DIS), Warner Bros. Discovery (WBD), Comcast (CMCSA) and Sony (SONY) benefit only where theatrical strength translates into downstream licensing, consumer-products and franchise value rather than simply higher marketing spend and talent participations.

The key question for the next 1-3 months is whether the improvement reflects sustainable admissions growth or price/mix-led gains concentrated in a handful of tentpoles. A concentrated slate can lift IMAX and exhibitors near term but does not necessarily repair weekday utilization or concession economics; domestic admissions, per-patron spending, film-rental terms and forward presales are the missing confirmation data. Over 6-18 months, a durable theatrical recovery would strengthen studios' negotiating leverage over streaming-window economics and could reduce the need for expensive direct-to-consumer content spend, especially at WBD and CMCSA.

Consensus may over-credit a strong box-office tape to highly levered AMC. AMC's capital structure means improved EBITDA first benefits creditors and only gradually changes equity value unless free cash flow becomes reliably positive after interest, maintenance capex and lease obligations. The more attractive relative expression is premium screens and financially resilient exhibitors, while maintaining skepticism toward a broad media rerating: theatrical revenue remains episodic and cannot alone offset linear-TV declines or streaming losses.

Key Decisions for Investors

• Initiate a 3-6 month long IMAX / short AMC pair: IMAX offers higher-quality premium-format exposure and asset-light economics, while AMC remains vulnerable to financing or dilution if cash generation disappoints. Reassess if AMC demonstrates sustained positive free cash flow after interest for two consecutive quarters or if the pair underperforms by 15%.
• Accumulate CNK on pullbacks over the next 1-3 months rather than chase broad studio equities: incremental attendance should produce outsized EBITDA conversion at a better balance-sheet risk profile than AMC. Thesis is falsified by weakening forward presales, declining concession spend per patron, or guidance indicating film-rental costs absorb the revenue upside.
• Use the next earnings cycle as a watch item for WBD and CMCSA: upgrade only if management links theatrical momentum to lower streaming-content cash burn, improved DTC profitability, or higher licensing income. Absent those metrics, treat box-office strength as insufficient to change the structural multiple-compression risk from legacy linear exposure.
• For event-driven exposure, consider defined-risk IMAX call spreads dated 4-6 months out only after confirming a premium-format-heavy release slate and accelerating advance sales; avoid naked AMC calls. The trade requires evidence that attendance—not merely ticket price—is improving.